Form 4 for IDYA IDEAYA Biosciences, Inc.
Accepted 2023-09-06 00:00:00 ET · period of report 2023-09-01 · accession 0001610717-23-000258 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DMT | 2023-09-06 | 2023-09-01+ | IDYA | Throne Jason | CLO | S - Sale+OE | $30.03 | -3,837 | 0 | -100% | -$115.2K |
| DMT | 2023-09-06 | 2023-09-01+ | IDYA | Throne Jason | CLO | M - OptEx | $12.86 | +3,837 | 2,100 | New | +$49.3K |
| DMT | 2023-09-06 | 2023-09-01+ | IDYA | Throne Jason | CLO | M - OptEx | $0.00 | -3,837 | 56.6K | -6% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-09-05 | S | D | 1,737 | $30.03 | 0 | D | — | — | (F3) This transaction was executed in multiple trades in prices ranging from $30.00 to $30.25, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. |
| 2 | Common | Common Stock | 2023-09-01 | S | D | 2,100 | $30.03 | 0 | D | — | — | (F2) This transaction was executed in multiple trades in prices ranging from $30.00 to $30.10, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. |
| 3 | Common | Common Stock | 2023-09-05 | M | A | 1,737 | $12.86 | 1,737 | D | — | — | |
| 4 | Common | Common Stock | 2023-09-01 | M | A | 2,100 | $12.86 | 2,100 | D | — | — | |
| 5 | Derivative | Stock Option (Right to Buy) | 2023-09-05 | M | D | 1,737 | $0.00 | 54,913 | D | $12.86 · — to 2032-02-29 | 1,737 Common Stock | (F4) 25% of the shares subject to the option vest on the first anniversary measured from January 1, 2022 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date. |
| 6 | Derivative | Stock Option (Right to Buy) | 2023-09-01 | M | D | 2,100 | $0.00 | 56,650 | D | $12.86 · — to 2032-02-29 | 2,100 Common Stock | (F4) 25% of the shares subject to the option vest on the first anniversary measured from January 1, 2022 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date. |